CCL2 and neoplasm: CCL2 was at first characterized as a “tumor‐derived chemokine” and has been documented to be a potent chemotactic agent for a couple of immune cells (e.g., monocytes, immature dendritic cells (DCs), memory T cells, and natural killer (NK) cells), thereby promoting inflammatory effects and neoangiogenesis.